JP Morgan reiterated its Overweight rating on NxStage Medical NXTM. At the same time, the rating agency left its price target on the company's stock unchanged at $26. On Friday, NXTM closed the day at $20.98.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
